Recombinant BetaKine: Began a Phase III trial in 120 patients

Celtrix Pharamaceuticals Inc. (CRTX) Product: Recombinant BetaKine, transforming growth factor-beta-2 Indication: Treatment of macular holes Status: Began a Phase III trial in 120 patients ...